You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTolazamide
Accession NumberDB00839  (APRD01267)
TypeSmall Molecule
GroupsApproved
DescriptionA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide. [PubChem]
Structure
Thumb
Synonyms
1-(hexahydro-1-Azepinyl)-3-P-tolylsulfonylurea
1-(hexahydro-1H-Azepin-1-yl)-3-(P-tolylsulfonyl)urea
4-(P-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide
BRN 1323565
CCRIS 591
Diabewas
EINECS 214-588-3
N-(P-Toluenesulfonyl)-n'-hexamethyleniminourea
N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide
Norglycin
Tolazamid
Tolazamida
Tolazamide
Tolazamidum
Tolinase
U 17835
U-17835
External Identifiers
  • U 17835
Approved Prescription ProductsNot Available
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TolazamideTablet250 mg/1OralMylan Pharmaceuticals Inc.2013-01-18Not applicableUs
TolazamideTablet500 mg/1OralMylan Pharmaceuticals Inc.2013-01-18Not applicableUs
TolazamideTablet250 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DesumideHua Shin
EsulinChung Mei
NorglycinPfizer
TolanaseUpjohn
TolinaseNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9LT1BRO48Q
CAS number1156-19-0
WeightAverage: 311.4
Monoisotopic: 311.130362243
Chemical FormulaC14H21N3O3S
InChI KeyOUDSBRTVNLOZBN-UHFFFAOYSA-N
InChI
InChI=1S/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)
IUPAC Name
1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea
SMILES
CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1
Pharmacology
IndicationFor use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.
Structured Indications
PharmacodynamicsTolazamide is an oral blood glucose lowering drug of the sulfonylurea class. Tolazamide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which tolazamide lowers blood glucose during long-term administration has not been clearly established. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonylurea hypoglycemic drugs. Some patients who are initially responsive to oral hypoglycemic drugs, including tolazamide, may become unresponsive or poorly responsive over time. Alternatively, tolazamide may be effective in some patients who have become unresponsive to one or more other sulfonylurea drugs. In addition to its blood glucose lowering actions, tolazamide produces a mild diuresis by enhancement of renal free water clearance.
Mechanism of actionSulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
TargetKindPharmacological actionActionsOrganismUniProt ID
ATP-sensitive inward rectifier potassium channel 1Proteinyes
inhibitor
HumanP48048 details
Related Articles
AbsorptionRapidly and well absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Tolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0 to 70%.

Route of eliminationTolazamide is metabolized to five major metabolites ranging in hypoglycemic activity from 0% to 70%. They are excreted principally in the urine.
Half lifeThe average biological half-life of the drug is 7 hours.
ClearanceNot Available
ToxicityOverdosage of sulfonylureas can produce hypoglycemia. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Tolazamide.Experimental
AcarboseAcarbose may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
AcebutololAcebutolol may increase the hypoglycemic activities of Tolazamide.Approved
AcenocoumarolTolazamide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Tolazamide.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
AicarAicar may increase the hypoglycemic activities of Tolazamide.Experimental
AlbiglutideAlbiglutide may increase the hypoglycemic activities of Tolazamide.Approved
AlogliptinAlogliptin may increase the hypoglycemic activities of Tolazamide.Approved
AlprenololAlprenolol may increase the hypoglycemic activities of Tolazamide.Approved, Withdrawn
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Tolazamide.Approved
Aop200704Aop200704 may increase the hypoglycemic activities of Tolazamide.Investigational
AripiprazoleThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the hypoglycemic activities of Tolazamide.Approved
Arsenic trioxideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypoglycemic activities of Tolazamide.Approved
AtorvastatinAtorvastatin may increase the hypoglycemic activities of Tolazamide.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Tolazamide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
BefunololBefunolol may increase the hypoglycemic activities of Tolazamide.Experimental
BendroflumethiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Tolazamide.Withdrawn
BetamethasoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypoglycemic activities of Tolazamide.Approved
BevantololBevantolol may increase the hypoglycemic activities of Tolazamide.Approved
BezafibrateBezafibrate may increase the hypoglycemic activities of Tolazamide.Approved
BisoprololBisoprolol may increase the hypoglycemic activities of Tolazamide.Approved
BopindololBopindolol may increase the hypoglycemic activities of Tolazamide.Approved
BrexpiprazoleThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Brexpiprazole.Approved
BucindololBucindolol may increase the hypoglycemic activities of Tolazamide.Investigational
BuforminBuformin may increase the hypoglycemic activities of Tolazamide.Withdrawn
BufuralolBufuralol may increase the hypoglycemic activities of Tolazamide.Experimental, Investigational
BumetanideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Bumetanide.Approved
BupranololBupranolol may increase the hypoglycemic activities of Tolazamide.Approved
BuserelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Buserelin.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Tolazamide.Approved
CarbocisteineThe risk or severity of adverse effects can be increased when Tolazamide is combined with Carbocisteine.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Tolazamide.Withdrawn
CarteololCarteolol may increase the hypoglycemic activities of Tolazamide.Approved
CarvedilolCarvedilol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Tolazamide.Experimental
CeliprololCeliprolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
CeritinibThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ceritinib.Approved
ChloramphenicolThe metabolism of Tolazamide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide.Approved, Vet Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Tolazamide.Approved
ChlorthalidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorthalidone.Approved
CiglitazoneCiglitazone may increase the hypoglycemic activities of Tolazamide.Experimental
CimetidineThe serum concentration of Tolazamide can be increased when it is combined with Cimetidine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Tolazamide.Approved, Withdrawn
CiprofibrateCiprofibrate may increase the hypoglycemic activities of Tolazamide.Approved
CiprofloxacinCiprofloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
CitalopramCitalopram may increase the hypoglycemic activities of Tolazamide.Approved
ClofibrateClofibrate may increase the hypoglycemic activities of Tolazamide.Approved
ClozapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Clozapine.Approved
CorticotropinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cortisone acetate.Approved
Cyproterone acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Danazol.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Tolazamide.Investigational
DarunavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Darunavir.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Tolazamide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Tolazamide.Investigational
DesogestrelThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Tolazamide.Approved
DexamethasoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Diazoxide.Approved
DicoumarolTolazamide may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Tolazamide.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Tolazamide.Illicit
DisopyramideDisopyramide may increase the hypoglycemic activities of Tolazamide.Approved
DrospirenoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Drospirenone.Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Tolazamide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Tolazamide.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Tolazamide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Tolazamide.Approved
EpinephrineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
EsmololEsmolol may increase the hypoglycemic activities of Tolazamide.Approved
EstradiolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.Approved
EthanolThe risk or severity of adverse effects can be increased when Tolazamide is combined with Ethanol.Approved
Ethinyl EstradiolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethyl biscoumacetateTolazamide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ethynodiol diacetate.Approved
EtofibrateEtofibrate may increase the hypoglycemic activities of Tolazamide.Approved
EtonogestrelThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Tolazamide.Approved
EverolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Everolimus.Approved
ExenatideExenatide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
FenofibrateFenofibrate may increase the hypoglycemic activities of Tolazamide.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Tolazamide.Approved
FluconazoleThe serum concentration of Tolazamide can be increased when it is combined with Fluconazole.Approved
FludrocortisoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fludrocortisone.Approved
FluindioneTolazamide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Tolazamide.Withdrawn
FluoxetineFluoxetine may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Tolazamide.Approved, Illicit
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fosamprenavir.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
FurosemideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Furosemide.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Tolazamide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
GemfibrozilGemfibrozil may increase the hypoglycemic activities of Tolazamide.Approved
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Tolazamide.Withdrawn
GliclazideTolazamide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Tolazamide.Approved
GlipizideTolazamide may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Tolazamide.Approved
GlyburideTolazamide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Tolazamide.Withdrawn
GusperimusGusperimus may increase the hypoglycemic activities of Tolazamide.Investigational
HistrelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Tolazamide.Approved
HydrochlorothiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Iloperidone.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Tolazamide.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indapamide.Approved
IndenololIndenolol may increase the hypoglycemic activities of Tolazamide.Withdrawn
IndinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Indinavir.Approved
Insulin AspartTolazamide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirTolazamide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Tolazamide.Approved
Insulin GlulisineTolazamide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Tolazamide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Tolazamide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Tolazamide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Tolazamide.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Tolazamide.Approved
LabetalolLabetalol may increase the hypoglycemic activities of Tolazamide.Approved
LanreotideTolazamide may increase the hypoglycemic activities of Lanreotide.Approved
LeuprolideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the hypoglycemic activities of Tolazamide.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Tolazamide.Approved
LevonorgestrelThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LinagliptinLinagliptin may increase the hypoglycemic activities of Tolazamide.Approved
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Tolazamide.Approved, Nutraceutical
LiraglutideLiraglutide may increase the hypoglycemic activities of Tolazamide.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Tolazamide.Approved
LopinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lopinavir.Approved
LurasidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Tolazamide.Withdrawn
MecaserminTolazamide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Tolazamide.Approved
MestranolThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Mestranol.Approved
MetforminMetformin may increase the hypoglycemic activities of Tolazamide.Approved
MethotrimeprazineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methyclothiazide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Tolazamide.Investigational
MethylprednisoloneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Tolazamide.Approved
MetipranololMetipranolol may increase the hypoglycemic activities of Tolazamide.Approved
MetolazoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.Approved
MetoprololMetoprolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
MetreleptinMetreleptin may increase the hypoglycemic activities of Tolazamide.Approved
MiconazoleMiconazole may increase the hypoglycemic activities of Tolazamide.Approved, Investigational, Vet Approved
MifepristoneMifepristone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Tolazamide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Tolazamide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Tolazamide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Tolazamide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Tolazamide.Approved
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
NadololNadolol may increase the hypoglycemic activities of Tolazamide.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Tolazamide.Approved
NateglinideNateglinide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Tolazamide.Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Tolazamide.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Tolazamide.Investigational
NiacinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Tolazamide.Withdrawn
NilotinibThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Tolazamide.Investigational
NorethisteroneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Tolazamide.Approved
NorgestimateThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Norgestimate.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Tolazamide.Withdrawn
OctreotideOctreotide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Tolazamide.Approved
OlanzapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Olanzapine.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Tolazamide.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
OxprenololOxprenolol may increase the hypoglycemic activities of Tolazamide.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Tolazamide.Approved, Illicit
PaliperidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Paliperidone.Approved
PargylinePargyline may increase the hypoglycemic activities of Tolazamide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
PasireotideTolazamide may increase the hypoglycemic activities of Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Tolazamide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Tolazamide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Tolazamide.Approved
PenbutololPenbutolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
PentamidinePentamidine may increase the hypoglycemic activities of Tolazamide.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Tolazamide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Tolazamide.Approved, Withdrawn
PhenindioneTolazamide may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Tolazamide.Withdrawn
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Tolazamide.Withdrawn
PhenprocoumonTolazamide may increase the anticoagulant activities of Phenprocoumon.Approved
PindololPindolol may increase the hypoglycemic activities of Tolazamide.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
PiperazineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Tolazamide.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Tolazamide.Withdrawn
PolythiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Polythiazide.Approved
PractololPractolol may increase the hypoglycemic activities of Tolazamide.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
PrednisoloneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProbenecidThe protein binding of Tolazamide can be decreased when combined with Probenecid.Approved
ProgesteroneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropranololPropranolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Tolazamide.Investigational
QuetiapineThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quetiapine.Approved
QuinethazoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Quinethazone.Approved
QuinineQuinine may increase the hypoglycemic activities of Tolazamide.Approved
RanitidineThe serum concentration of Tolazamide can be increased when it is combined with Ranitidine.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Tolazamide.Approved
RepaglinideTolazamide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifampicinThe serum concentration of Tolazamide can be decreased when it is combined with Rifampicin.Approved
RisperidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ritonavir.Approved, Investigational
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Tolazamide.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Tolazamide.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
SaquinavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Tolazamide.Approved
SelegilineSelegiline may increase the hypoglycemic activities of Tolazamide.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Tolazamide.Approved
SirolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
SotalolSotalol may increase the hypoglycemic activities of Tolazamide.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Tolazamide.Approved
StanozololStanozolol may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
SulfamethoxazoleTolazamide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Tolazamide.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
SunitinibTolazamide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Tolazamide.Withdrawn
TemsirolimusThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Temsirolimus.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
ThiazolidinedioneThiazolidinedione may increase the hypoglycemic activities of Tolazamide.Investigational
TimololTimolol may increase the hypoglycemic activities of Tolazamide.Approved
TipranavirThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Tipranavir.Approved, Investigational
TolbutamideTolazamide may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Tolazamide.Approved
TorasemideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Tolazamide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Tolazamide.Approved
TriamcinoloneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Tolazamide.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Withdrawn
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Tolazamide.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
VoriconazoleThe serum concentration of Tolazamide can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Vorinostat.Approved, Investigational
WarfarinTolazamide may increase the anticoagulant activities of Warfarin.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Tolazamide.Withdrawn
ZiprasidoneThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesA10BB05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9749
Blood Brain Barrier+0.8467
Caco-2 permeable-0.6444
P-glycoprotein substrateSubstrate0.7039
P-glycoprotein inhibitor INon-inhibitor0.8125
P-glycoprotein inhibitor IINon-inhibitor0.9824
Renal organic cation transporterNon-inhibitor0.8497
CYP450 2C9 substrateSubstrate0.622
CYP450 2D6 substrateNon-substrate0.8816
CYP450 3A4 substrateNon-substrate0.7268
CYP450 1A2 substrateNon-inhibitor0.9274
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorNon-inhibitor0.9104
CYP450 3A4 inhibitorNon-inhibitor0.84
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.962
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8461
BiodegradationNot ready biodegradable0.7221
Rat acute toxicity1.8259 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8064
hERG inhibition (predictor II)Non-inhibitor0.8047
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Interpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Sandoz inc
  • Superpharm corp
  • Usl pharma inc
  • Watson laboratories inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg/1
TabletOral500 mg/1
Prices
Unit descriptionCostUnit
Tolazamide 500 mg tablet1.41USD tablet
Tolinase 250 mg tablet1.23USD tablet
Tolazamide 250 mg tablet0.79USD tablet
Tolazamide 100 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170-173 °CPhysProp
water solubility65.4 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.69SANGSTER (1993)
logS-3.68ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.308 mg/mLALOGPS
logP1.4ALOGPS
logP1.91ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)4.07ChemAxon
pKa (Strongest Basic)1.61ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.51 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity81.34 m3·mol-1ChemAxon
Polarizability32.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-06r6-9500000000-41e71d724a7515763bb7View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentBenzenesulfonamides
Alternative Parents
Substituents
  • Tosyl compound
  • Benzenesulfonamide
  • Toluene
  • Sulfonylurea
  • Azepane
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Semicarbazide
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Phosphatidylinositol-4,5-bisphosphate binding
Specific Function:
In the kidney, probably plays a major role in potassium homeostasis. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive vol...
Gene Name:
KCNJ1
Uniprot ID:
P48048
Molecular Weight:
44794.6 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Szabo C, Salzman AL: Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4. [PubMed:8799949 ]
  4. Asano K, Cortes P, Garvin JL, Riser BL, Rodriguez-Barbero A, Szamosfalvi B, Yee J: Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Kidney Int. 1999 Jun;55(6):2289-98. [PubMed:10354277 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23